James Larkin
James Larkin
Royal Marsden NHS Foundation Trust, Institute of Cancer Research
Verified email at rmh.nhs.uk
Cited by
Cited by
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ...
New England Journal of Medicine 364 (26), 2507-2516, 2011
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
M Gerlinger, AJ Rowan, S Horswell, J Larkin, D Endesfelder, E Gronroos, ...
N Engl j Med 366, 883-892, 2012
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ...
New England journal of medicine 373 (1), 23-34, 2015
Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
New England Journal of Medicine 372 (26), 2521-2532, 2015
Nivolumab versus everolimus in advanced renal-cell carcinoma
RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ...
New England Journal of Medicine 373 (19), 1803-1813, 2015
Improved survival with MEK inhibition in BRAF-mutated melanoma
KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ...
New England Journal of Medicine 367 (2), 107-114, 2012
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ...
The lancet oncology 16 (4), 375-384, 2015
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalŕ, ...
New England Journal of Medicine 371 (20), 1867-1876, 2014
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
New England Journal of Medicine 371 (20), 1877-1888, 2014
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
M Gerlinger, S Horswell, J Larkin, AJ Rowan, MP Salm, I Varela, R Fisher, ...
Nature genetics 46 (3), 225, 2014
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ...
The Lancet 386 (9992), 444-451, 2015
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ...
The lancet oncology 15 (3), 323-332, 2014
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ...
New England Journal of Medicine 377 (19), 1824-1835, 2017
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Haanen, F Carbonnel, C Robert, KM Kerr, S Peters, J Larkin, K Jordan
Annals of Oncology 28 (suppl_4), iv119-iv142, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
GV Long, A Hauschild, M Santinami, V Atkinson, M Mandalŕ, ...
New England Journal of Medicine 377 (19), 1813-1823, 2017
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
RJ Motzer, TE Hutson, H Glen, MD Michaelson, A Molina, T Eisen, ...
The lancet oncology 16 (15), 1473-1482, 2015
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ...
New England Journal of Medicine 378 (19), 1789-1801, 2018
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
The Lancet 390 (10105), 1853-1862, 2017
Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma.
JS Weber, FS Hodi, JD Wolchok, SL Topalian, D Schadendorf, J Larkin, ...
The system can't perform the operation now. Try again later.
Articles 1–20